Phosphorylation modification of alpha synuclein in serum of patients with Parkinson’s disease

doi:10.12307/2024.205

Abstract

Abstract: BACKGROUND: The aggregates formed after translational modification of α-synuclein are the main pathological changes of Parkinson’s disease. α-Synuclein can penetrate the blood-brain barrier and be delivered from the central nervous system to the peripheral blood to all parts of the body, which becomes an important pathway for the pathological dissemination of Parkinson’s disease. Therefore, it is particularly important to study the changes of blood markers in patients with Parkinson’s disease to reveal the mechanism of Parkinson‘s disease as well as for early diagnosis.
OBJECTIVE: To analyze the differences in the structural stability of phosphorylation modification sites and generated aggregates of α-synuclein in serum of patients with Parkinson’s disease.
METHODS: A recombinant human α-synuclein prokaryotic expression system was constructed, and the protein was purified by affinity chromatography. The purity and specificity of α-synuclein monomer was detected by SDS-PAGE and western blot. Serum samples of 26 normal controls and 26 patients with Parkinson’s disease in the Department of Neurology, Affiliated Hospital of Beihua University were collected to complete the preparation of serum α-synuclein aggregates. The modified sites for phosphorylation modification of α-synuclein protein in normal serum and serum of patients with Parkinson’s disease were identified using SWATH-mass spectrometry, and protein aggregates at different sites were quantitatively analyzed. The protein aggregates with different phosphorylation modifications were purified by immunoaffinity chromatography, and then detected for stability in the serum of patients with Parkinson’s disease by western blot.
RESULTS AND CONCLUSION: The results of SDS-PAGE and western blot showed that α-synuclein monomers with high purity and specificity were obtained. The results of the SWATH-mass spectrometry analysis showed that phosphorylation modifications occurred in both Parkinson’s disease patients and normal human serum, with significantly more phosphorylated sites in Parkinson’s disease patients than in normal humans. The phosphorylation sites in the serum of patients with Parkinson’s disease were Serine (Ser) 87, Ser129, L-tyrosine (Tyr)125, Tyr 133 and Tyr 136. After incubation in the serum of patients with Parkinson’s disease for α-synuclein, the phosphorylation modification at Ser129 accounted for 53.65% of the total phosphorylation, with 17.21%, 15.79%, 15.79%, 9.52%, and 1.03% for Tyr125, Tyr133, Tyr136, and Ser87, respectively. The serum levels of Ser129 phosphorylation-modified aggregates were detected by western blot to be more stable than those of Tyr125, Tyr133 and Tyr136 in patients with Parkinson’s disease. To conclude, the number of α-synuclein phosphorylation modification sites in the serum of patients with Parkinson’s disease was significantly higher than that of normal subjects. The aggregate structure generated by phosphorylation modification at Ser129 in the serum of patients with Parkinson’s disease was the most stable. This may provide a diagnostic marker for the early diagnosis of Parkinson’s disease.

Key words: , α-synuclein, Parkinson’s disease, phosphorylation, serum, serine, tyrosine, aggregate, diagnostic biomarker

CLC Number:

Qi Xue, Li Jiahui, Zhu Yuanfeng, Yu Lu, Wang Peng. Phosphorylation modification of alpha synuclein in serum of patients with Parkinson’s disease[J]. Chinese Journal of Tissue Engineering Research, 2023, 27(35): 5577-5582.

Figures/Tables 5

References

[1] HAYES MT. Parkinson’s Disease and Parkinsonism. Am J Med. 2019; 132(7):802-807.
[2] GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019; 18(5):459-480.
[3] WEINTRAUB D, MAMIKONYAN E. The neuropsychiatry of Parkinson disease: a perfect storm. Am J Geriatr Psychiatry. 2019;27(9):998-1018.
[4] ZHENGYU S, SHUAI L, XIYU L, et al. Prevalence of Parkinson’s disease in adults aged 65 years and older in china: a multicenter population-based survey. Neuroepidemiology. 2022;56(1):50-58.
[5] YU RC, PARK SJ, SANG MP. Molecular events underlying the cell‐to‐cell transmission of α‐synuclein. The FEBS Journal. 2021;288(23):6593-6602.
[6] BRAAK H, DEL TREDICI K, RÜB U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24(2): 197-211.
[7] CHAN PY, RIPIN ZM, HALIM SA, et al. Motion characteristics of subclinical tremors in Parkinson’s disease and normal subjects. Sci Rep. 2022;12(1):4021.
[8] SIMONET C, SCHRAG A, LEESs AJ, et al. The motor prodromes of parkinson’s disease: from bedside observation to large-scale application. J Neurol. 2021;268(6):2099-2108.
[9] MAROTEAUX L, CAMPANELLI JT, SCHELLER RH. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci. 1988;8(8):2804-2815.
[10] SORRENTINO ZA, HASS E, VIJAYAYAGHAVAN N, et al. Corrigendum to “Carboxy-terminal truncation and phosphorylation of α-synuclein elongates survival in a prion-like seeding mouse model of synucleinopathy” [Neurosci. Lett. 732 (2020) 1-11/135017]. Neurosci Lett. 2022;783:136719.
[11] PERINAN MT, BROLIN K, BANDRES-CIGA S, et al. Effect modification between genes and environment and Parkinson’s disease risk. Ann Neurol. 2022;92(5):715-724.
[12] KAWAHATA I, FINKELSTEIN DI, FUKUNAGA K. Pathogenic impact of α-synuclein phosphorylation and its kinases in α-synucleinopathies. Int J Mol Sci. 2022;23(11):6216.
[13] 安俊言,安思训,王鹏.帕金森病患者血清polo样激酶2活性升高促进α-突触核蛋白聚集[J].吉林医药学院学报,2019,40(3):171-174.
[14] MOORS TE, MONA D, LUEHE S, et al. Multi-platform quantitation of alpha-synuclein human brain proteoforms suggests disease-specific biochemical profiles of synucleinopathies. Acta Neuropathol Commun. 2022;10(1):1-22.
[15] 中华医学会神经病学分会帕金森病及运动障碍学组,中国医师协会神经内科医师分会帕金森病及运动障碍专业.中国帕金森病的诊断标准(2016版)[J].中华神经科杂志,2016,49(4):268-271.
[16] HASIN D, HATENBUEHLER ML, KEYES K, et al. Substance use disorders: Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) and International Classification of Diseases, tenth edition (ICD-10). Addiction. 2006;101(s1):59-75.
[17] JANKOVIC J, TAN EK. Parkinson’s disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2020;91(8):795-808.
[18] CHOOG CJ, MOCHIZUKI H. Neuropathology of α-synuclein in Parkinson’s disease. Neuropathology. 2022;42(2):93-103.
[19] BAEK MS, LEE MJ, KIM HK, et al. Temporal trajectory of biofluid markers in Parkinson’s disease. Sci Rep. 2021;11:14820.
[20] CHIU PY, YANG FC, CHIU MJ, et al. Relevance of plasma biomarkers to pathologies in Alzheimer’s disease, Parkinson’s disease and frontotemporal dementia. Sci Rep. 2022;12(1):17919.
[21] FUJIWARA H, HASEGAWA M, DOHMAE N, et al. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002;4(2): 160-164.
[22] YANG Y, SHI Y, SCHWEIGHAUSER M, et al. Structures of α-synuclein filaments from human brains with Lewy pathology. Nature. 2022; 610(7933):791-795.
[23] SILVA-COSTA LC, SMITH BJ. Post-translational modifications in brain diseases: a future for biomarkers. Adv Exp Med Biol. 2022;1382:129-141.
[24] WANG J, TAN Y, PENG Q, et al. Structural brain changes in Ser129-phosphorylated alpha-synuclein rats based on voxel-based morphometry. Behav Brain Res. 2020;393:112786.
[25] 杨智源,吕春香,王鹏.重组人α-突触核蛋白原核表达系统的建立及纯化方法[J].中国老年学杂志,2011,31(9):1616-1618.
[26] SANO K, IWASAKI Y, YAMASHITA Y, et al. Tyrosine 136 phosphorylation of α-synuclein aggregates in the Lewy body dementia brain: involvement of serine 129 phosphorylation by casein kinase 2. Acta Neuropathol Commun. 2021;9(1):182.
[27] MA L, YANG C, ZHANG X, et al. C-terminal truncation exacerbates the aggregation and cytotoxicity of α-Synuclein: a vicious cycle in Parkinson’s disease. Biochim Biophys Acta Mol Basis Dis. 2018; 1864(12):3714-3725.
[28] MAROTTA NP, ARA J, Uemura N, et al. Alpha-synuclein from patient Lewy bodies exhibits distinct pathological activity that can be propagated in vitro. Acta Neuropathol Commun. 2021;9(1):1-18.
[29] LASSEN LB, THOMSEN MS, BASSO E, et al. Mutation of tyrosine sites in the human alpha-synuclein gene induces neurotoxicity in transgenic mice with soluble alpha-synuclein oligomer formation. Cells. 2022; 11(22):3673.
[30] WU W, SUNG CC, YU P, et al. Correction: S-Nitrosylation of G protein-coupled receptor kinase 6 and Casein kinase 2 alpha modulates their kinase activity toward alpha-synuclein phosphorylation in an animal model of Parkinson’s disease. PLoS One. 2020;15(6):e0235296.
[31] KOSS DJ, ERSKINE D, PORTER A, et al. Nuclear alpha-synuclein is present in the human brain and is modified in dementia with Lewy bodies. Acta Neuropathol Commun. 2022;10(1):98.
[32] DING J, WANG Y, HUANG J, et al. Role of alpha-synuclein phosphorylation at Serine 129 in methamphetamine-induced neurotoxicity in vitro and in vivo. NeuroReport. 2020;31(11):787-797.